Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT07399795

Citalopram and the Risk of Serious Adverse Events

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

View on ClinicalTrials.gov

Summary

This population-based cohort study aims to evaluate the safety of initiating a new outpatient prescription of citalopram at 20 mg/day (higher dose) compared to 10 mg/day (lower dose) in adults aged 65 years and older with reduced kidney function. The primary research question is whether initiating a higher dose of citalopram (20 mg/day) versus a lower dose (10 mg/day) in older adults with low kidney function (defined as an estimated glomerular filtration rate \[eGFR\] less than 45 mL/min per 1.73 m2, without dialysis or a history of kidney transplantation) is associated with an increased 30-day risk of a composite outcome comprising all-cause hospitalization, all-cause emergency department visits, or all-cause mortality.

Official title: Citalopram Dose and the Risk of Serious Adverse Events in Older Adults With Low Kidney Function: A Population-Based Cohort Study Research Protocol

Key Details

Gender

All

Age Range

66 Years - Any

Study Type

OBSERVATIONAL

Enrollment

7110

Start Date

2008-01-01

Completion Date

2027-12-31

Last Updated

2026-09-14

Healthy Volunteers

No

Interventions

DRUG

Citalopram 10 MG

The primary exposure of interest will be oral Citalopram at a dose of 10 or 20 mg/day.

DRUG

Citalopram 20 MG

The primary exposure of interest will be oral Citalopram at a dose of 10 or 20 mg/day.

Locations (1)

London Health Sciences Centre Research Institute

London, Ontario, Canada